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ABSTRACT  
Background: B-cell chronic lymphocytic leukaemia (B-CLL) is a B-cell neoplasm that in 
many patients shows an indolent course and survive for a prolonged period without 
therapy, but in others, CLL progresses rapidly and they die of the disease. Because of the 
difficulty in identifying such patients at diagnosis, only patients with progressive or 
symptomatic disease currently are recommended for therapy. Although easily 
characterized by diagnostic markers, the evaluation of an individual CLL patient’s 
prognosis remains a problematic issue. .  
Methods: We have performed a simple six colours flow cytometry assay for ZAP-70 in 
peripheral blood of 5 healthy donors and 20 B-CLL patients. Samples were incubated with 
the following monoclonal antibodies: anti CD3-PerCP, anti CD5 FITC anti CD38-APC, 
anti CD45 APC Cy-7, anti CD19 PE Cy-7, treated with the Intrasure kit and finally stained 
with the anti-human/mouse ZAP-70-PE conjugate. Samples were acquired on a 
FACSCanto flow cytometry and analyzed with FacsDiva software (Becton-Dickinson). 
Quantification of CLLU1 expression in CD19+ cells of donors and buffy coat of patients 
was performed with the use of CLLU-1 ProfileQuant Kit (Ipsogen) by RQ-PCR.  
Conclusion: About ZAP-70, the ratio between B-MFI/ T-MFI could be used to 
discriminate positive and negative patients instead of T-cells residual method. About 
CLLU-1 expression we have analyzed 5 healthy donors and 20 patients, donors showed 
very low levels of expression of the gene while CLL patients showed variable levels of 
expression. 
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1 INTRODUCTION 
1.1 B-cell chronic lymphocytic leukemia 
 
B-cell chronic lymphocytic leukemia (B-CLL) is a B-cell neoplasm characterized by an 
indolent course with progressive splenic and lymph node enlargement associated with 
chronic lymphocytosis. This disease is related to the accumulation of monoclonal B cells 
with the morphology of small mature lymphocytes. 
With an age-adjusted incidence of 4.1/100,000 inhabitants, chronic lymphocytic leukemia 
(CLL) is the most common type of leukemia in western countries. More than 15,000 newly 
diagnosed cases and 4,500 deaths are currently estimated
1
. The median age at diagnosis 
lies between 67 and 72 years. More male than female patients (1.7:1) are affected 
2
. 
As the incidence rate rises with age, the prevalence and mortality of CLL are likely to 
increase further due to the demographic changes in society in the forthcoming decades. 
Moreover,the proportion of younger patients with early stage CLL and minimal symptoms 
seems to increase due to more frequent blood testing
3
. CLL is characterized by the clonal 
proliferation and accumulation of mature, typically CD5-positive B-cells within the blood, 
bone marrow, lymph nodes, and spleen
4
. Very recently, it has been reported that in CLL 
the capacity to generate clonal B cells might be acquired at the hematopoietic stem cell 
(HSC) stage, suggesting that the primary leukemogenic event in CLL might involve 
multipotent, self-renewing HSCs. The leukemic transformation is initiated by specific 
genomic alterations causing the deletion of specific micro-RNA genes and increasing the 
resistance of B cells towards apoptosis. Deletions on the long arm of chromosome 13, 
specifically involving band 13q14 (del(13q14)) represent the single most frequently 
observed cytogenetic aberration in CLL, occurring in approx. 55% of all cases. An isolated 
del(13q14) is typically characterized by a benign course of the disease. The miRNAs, miR-
15a and 16-1, were recently identified to be located in the critical region of del(13q14)
5
. 
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The pathophysiologic role of these miRNAs is further underscored by the phenotype of 
genetically engineered mice carrying a targeted deletion of the mir- 15a/16-1 locus in 
combination with a deletion of the noncoding RNA gene DLEU2. These animals develop a 
monoclonal B-cell lymphocytosis-like disorder, CLL, and lymphoma, suggesting that the 
miRNAs 15a and 16-1 indeed play a role in CLL leukemogenesis
6
. Deletions of the long 
arm of chromosome 11 (del(11q)) can be found in 25% of chemotherapy-naıve patients 
with advanced disease stages and 10% of patients with early stage disease
7
. These 
deletions frequently encompass band 11q23 harbouring the gene ATM, which encodes for 
the proximal DNA damage response kinase ATM. In addition, patients carrying a del(11q) 
clone typically show a bulky lymphadenopathy, rapid progression, and reduced overall 
survival
8
. Interestingly, some of the poor prognostic features of del(11q) seem to be 
overcome by the use of chemoimmunotherapy
9
. Trisomy 12 is observed in 10–20% of 
CLL patients. However, the genes involved in the pathogenesis of CLLs carrying a trisomy 
12 are largely unknown. Furthermore, the prognostic relevance of trisomy 12 remains a 
matter of debate
10
. Deletions of the short arm of chromosome 17 (del(17p)) are found in 5–
8% of chemotherapy-naıve patients. These deletions almost always include band 17p13, 
where the prominent tumor suppressor gene TP53 is located. CLL patients carrying a 
del(17p) clone show marked resistance against genotoxic chemotherapies that cannot be 
overcome by the addition of anti-CD20 antibodies in the context of state of the art chemo-
immunotherapy
9
. Mutations of TP53 are found in 4–37% of patients with CLL, and have 
been associated with very poor prognosis
11
. Among cases with confirmed del(17p), the 
majority show mutations in the remaining TP53 allele (>80%). In cases without del(17p), 
TP53 mutations are much rarer, but have a similarly detrimental effect on chemotherapy 
response and overall survival
10
. TP53 mutations are also associated with higher genomic 
complexity in CLL, indicating that a crippled DDR promotes a “mutator phenotype” in 
CLL
10
. The recently reported whole genome sequencing projects in CLL have revealed a 
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number of recurrent somatic gene mutations that occur in parallel to the abovementioned 
structural genomic aberrations. These include the genes NOTCH1, MYD88, TP53, ATM, 
SF3B1, FBXW7, POT1, CHD2, and others
7
. Of note, TP53, ATM, POT1, and CHD2 
encode for proteins critically involved in DNA damage signaling and DNA repair
12
. 
Intriguingly, both del(17p) and del(11q), as well as inactivating somatic mutations in TP53 
and ATM are enriched in patients with secondary resistance to DNA-damaging 
chemotherapy
7
. This observation underscores the critical importance of the ATM-Chk2-
p53 signaling axis in mediating apoptosis in response to DNA damage in CLL. Survival of 
CLL cells strictly depends on a permissive microenvironment composed of cellular 
components like macrophages, T cells, or stromal follicular dendritic cells providing 
stimuli for activation of crucial survival and proproliferative signaling pathways in 
transformed cells
13
. This microenvironment produces various essential proteins 
(chemokines, cytokines, and angiogenic factors) that interact with leukemic cells via 
appropriate surface receptors or adhesion molecules to support the survival of CLL cells
14
. 
In light of these important advances it is not surprising that the management of this 
leukemia is constantly undergoing important changes that have started 20 years ago and 
still gain in dynamics 
15
. Several new drugs have been approved (fludarabine, 
bendamustine as well as three monoclonal antibodies, alemtuzumab, rituximab, and 
ofatumumab). Chemoimmunotherapies composed of fludarabine and rituximab (with our 
without cyclophosphamide), or of fludarabine and alemtuzumab have shown to improve 
overall survival when used as therapy for CLL patients. In addition, several specific 
inhibitors interrupting.  
Typically, B-CLL cells exhibit a characteristic immunophenotype, co-expressing CD19, 
CD5 and CD23, in the absence or low expression of surface CD22, CD79b and 
FMC7.Surface immunoglobulins are clonal but weakly expressed or undetectable. Patients 
with B-CLL have heterogeneous courses. Some survive for a long time without therapy, 
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while others die rapidly despite aggressive treatment. Recently, breakthroughs have been 
made in the identification of molecular and cellular markers that may predict disease 
progression  
1.1.1 Diagnosis 
 
In most cases the diagnosis of CLL is established by blood counts, differential counts, a 
blood smear, and immunophenotyping. The World Health Organization (WHO) 
classification of hematopoietic neoplasias describes CLL as leukemic, lymphocytic 
lymphoma, being only distinguishable from SLL (small lymphocytic lymphoma) by its 
leukemic appearance
16
.  
The diagnosis of CLL requires the presence of 5,000 B-lymphocytes/mL in the peripheral 
blood for the duration of at least 3 months. The clonality of the circulating B-lymphocytes 
needs to be confirmed by flow cytometry. The leukemia cells found in the blood smear are 
characteristically small, mature lymphocytes with a narrow border of cytoplasm and a 
dense nucleus lacking discernible nucleoli and having partially aggregated chromatin. 
These cells may be found admixed with larger or atypical cells, cleaved cells, or 
prolymphocytes, which may comprise up to 55% of the blood lymphocytes
17
. Finding 
prolymphocytes in excess of this percentage would favor a diagnosis of prolymphocytic 
leukemia (B-cell PLL). Gumprecht nuclear shadows, or smudge cells, found as cell debris, 
are other characteristic morphologic features found in CLL.  
In the absence of lymphadenopathy or organomegaly (as defined by physical examination 
or CT scans), cytopenias, or disease-related symptoms, the presence of fewer than 5,000 B-
lymphocytes per µL blood is defined as “monoclonal B-lymphocytosis” (MBL)18. The 
presence of a cytopenia caused by a typical marrow infiltrate defines the diagnosis of CLL 
regardless of the number of peripheral blood B-lymphocytes or of the lymphnode 
involvement. MBL seems to progress to frank CLL at a rate of 1–2% per year19 
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.The definition of SLL requires the presence of lymphadenopathy and the absence of 
cytopenias caused by a clonal marrow infiltrate. Moreover, the number of B-lymphocytes 
in the peripheral blood should not exceed 5,000/µL. In SLL, the diagnosis should be 
confirmed by histopathological evaluation of a lymph node biopsy whenever possible. 
 
1.1.2 Treatment 
 
Two widely accepted staging methods co-exist, the Rai
20
 and the Binet system
21
. The 
original Rai classification was modified to reduce the number of prognostic groups from 
five to three
20
. Both systems describe three major prognostic groups with discrete clinical 
outcomes. These two staging systems are simple, inexpensive, and solely rely on a physical 
examination and standard laboratory tests. They do not require ultrasound, computed 
tomography, or magnetic resonance imaging.  
The modified Rai staging system defines: 
 Low-risk disease as patients who have lymphocytosis with leukemia cells in the 
blood and/or marrow (lymphoid cells >30%) (former Rai stage 0).  
 Patients with lymphocytosis, enlarged nodes in any site, and splenomegaly and/or 
hepatomegaly annual clinical updates in hematological malignancies (lymph nodes 
being palpable or not) are defined as having intermediate risk disease (formerly 
considered Rai Stages I or II).  
 High risk disease includes patients with disease-related anemia (as defined by a 
hemoglobin (Hb) level less than 11 g/dL) (formerly Stage III) or thrombocytopenia 
(as defined by a platelet count of less than 100 x 10
9
/L) (formerly Stage IV).  
The Binet staging system is based on the number of involved areas, as defined by 
the presence of enlarged lymph nodes of greater than 1 cm in diameter or 
organomegaly, and on whether there is anemia or thrombocytopenia. The areas of 
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involvement considered are (1) head and neck, including the Waldeyer ring (this 
counts as one area, even if more than one group of nodes is enlarged). (2) axillae 
(involvement of both axillae counts as one area). (3) Groins, including superficial 
femoral (involvement of both groins counts as one area). (4) Palpable spleen. (5) 
Palpable liver (clinically enlarged). Binet stages are defined as follows: 
 Stage A. Hb > 10 g/dL and platelets >100 x 109/L and up to two of the above 
involved. 
 Stage B. Hb > 10 g/dL and platelets >100 x 109/L and organomegaly greater than 
that defined for Stage A (i.e.,three or more areas of nodal or organ enlargement). 
 Stage C. All patients who have Hb of less than 10 g/dL and/or a platelet count of 
less than 100 x 10
9
/L irrespective of organomegaly. 
Criteria for initiating treatment may vary depending on whether or not the patient is treated 
in a clinical trial. In general practice, newly diagnosed patients with asymptomatic early-
stage disease (Rai 0, Binet A), should be monitored without therapy unless they have 
evidence of disease progression. Studies from both the French Cooperative Group on 
CLL
22
, the Cancer and Leukemia Group B (CALGB)
23
, and the Spanish Group Pethema
24
 
in patients with earlystage disease showed that the use of alkylating agents did not prolong 
survival in this specific situation. This result was confirmed by a meta-analysis
25
. In one 
study, treated patients with early-stage disease had an increased frequency of fatal 
epithelial cancers compared with untreated patients
22
. Therefore, the potential benefit of an 
early-intervention therapy with anti-leukemia drugs remains to be proven. Whereas 
patients at intermediate (Stages I and II) and high risk (Stages III and IV) according to the 
modified Rai classification or at Binet Stage B or C usually benefit from the initiation of 
treatment, some of these patients (in particular Rai intermediate risk or Binet stage B) can 
be monitored without therapy until they have evidence for progressive or 
symptomatic/active disease as defined by CLL guidelines: 
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o evidence of progressive marrow failure (anemia and/or thrombocytopenia); 
o massive (i.e.,6 cm below the left costal margin) or progressive or 
symptomatic splenomegaly; 
o massive nodes (i.e.,10 cm in longest diameter) or progressive or 
symptomatic lymphadenopathy; 
o progressive lymphocytosis with an increase of>50% over a 2-month period; 
o lymphocyte doubling time (LDT) of less than 6 months; 
o autoimmune anemia and/or thrombocytopenia that is poorly responsive to 
corticosteroids or other standard therapy; 
o disease-related symptoms such as unintentional weight loss 10% within the 
previous 6 months, significant fatigue, fevers of greater than 38.0°C for 2 or 
more weeks without other evidence of infection; 
o or night sweats for more than 1 month without evidence of infection. 
Patients with initial blood lymphocyte counts of less than 30.000/µL may require a longer 
observation period to determine the LDT. Also, factors contributing to lymphocytosis or 
lymphadenopathy other than CLL (e.g., infections) should be excluded. 
Patients with CLL may present with a markedly elevated leukocyte count; however, the 
symptoms associated with leukocyte aggregates that develop in patients with acute 
leukemia rarely occur in patients with CLL. Therefore, the absolute lymphocyte count 
should not be used as the sole indicator for treatment. 
Several genetic markers, in particular some of the above defined genetic and chromosomal 
aberrations, have been described to add prognostic information to these two staging 
systems, but so far there is no consensus or evidence that the use of additional markers is 
needed in general practice to define a treatment indication
26
. It is anticipated that the 
prognostic classification might change in the near future (Bahlo et al., submitted). 
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Response Assessment 
 
In essence the following response categories can be separated:  
complete remission, partial remission, stable disease, and progression, as well as refractory 
disease. In addition, the assessment of minimal residual disease (MRD) has been 
introduced as an additional and increasingly important category of response assessment.  
1.1.3 Treatment Components 
 
1.1.3.1 Single Agents 
Cytostatic agents. Monotherapy with alkylating agents has served as initial, front-line 
therapy for CLL, and chlorambucil has been considered the “gold standard” for several 
decades
25
. Even today, this drug remains an appropriate option, particularly in frail elderly 
or unfit patients. The advantages of chlorambucil are its low toxicity, low cost, and 
convenience as an oral drug; the major disadvantages are its low to nonexistent CR rate 
and some side effects that occur after extended use (prolonged cytopenia, myelodysplasia, 
and secondary acute leukemia). 
Novel results indicate that chlorambucil monotherapy may be used less frequently, since 
the combination with anti-CD20 antibodies has proven more effective. 
Three purine analogues are currently used in CLL: fludarabine, pentostatin, and cladribine 
(2-CdA). Fludarabine monotherapy produces superior overall response (OR) rates 
compared with other treatment regimens containing alkylating agents or corticosteroids
27
. 
Fludarabine induced more remissions and more complete remissions (CR) (7–40%) than 
other conventional chemotherapies, like CHOP (cyclophosphamide, doxorubicin, 
vincristine, prednisone), CAP (cyclophosphamide, doxorubicin, prednisone), or 
chlorambucil, but did not improve overall survival when used as single agent
27
. Similarly, 
cladribine monotherapy was shown to produce a higher CR rate than chlorambucil plus 
prednisone (47% vs.12%) without resulting in a longer survival
28
. More recently, 
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bendamustine, 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid, 
which has been used in Germany for more than 30 years, was compared with chlorambucil 
in a randomized trial. Bendamustine produced improved responses but greater toxicity
29
.  
1.1.3.2 Monoclonal Antibodies 
Anti-CD20 antibodies 
CD20 is an activated, glycosylated phosphoprotein expressed on the surface of mature 
Bcells. The protein has no known natural ligand
30
 and its function is not yet discovered. It 
is suspected to act as a calcium channel in the cell membrane. As CD20 is expressed on 
most B-cell malignancies, the introduction of the anti-CD20 antibody Rituximab in 1998 
improved the treatment of most CD20-positive non-Hodgkin lymphomas including CLL 
31
.  
In CLL, Rituximab is less active as a single agent than in follicular lymphoma, unless very 
high doses are used 
32
. In contrast, combinations of rituximab with chemotherapy have 
proven to be very efficacious therapies for CLL. Ofatumumab is a fully humanized 
antibody targeting a unique epitope on the CD20 molecule expressed on human B-cells, 
resulting in increased binding affinity to CD20, prolonged dissociation rate, and increased 
cell kill due to greater CDC activity and similar ADCC activity compared with Rituximab, 
especially in cells expressing low levels of CD20
33
.  
The humanized and glycoengineered monoclonal antibody Obinutuzumab showed 
impressive results in vitro with higher rates of apoptosis in B-cells in comparison to 
Rituximab
34
. The humanization of the parental B-Ly1 mouse antibody and subsequent 
glycol-engineering lead to higher affinity binding to CD20 type II epitope, increased 
antibody-dependent cellular cytotoxicity (ADCC), low complement-dependent cytotoxicity 
(CDC) activity, and increased direct cell death induction
35
. Major side effects included 
infections, neutropenia, thrombocytopenia, and tumor lysis syndrome, which all resolved. 
There were no dose-limiting toxicities. 
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1.1.1.3 Other Monoclonal Antibodies 
Alemtuzumab is a recombinant, fully humanized, monoclonal antibody against the CD52 
antigen.Alemtuzumab has proven effective in patients with high-risk genetic markers such 
as deletions of chromosome 11 or 17 (del(11q) and del(17p)) and TP53 mutations
36
. 
Therefore, alemtuzumab is considered a reasonable therapeutic option for patients with 
these poor prognostic features.  
1.1.3.4 New Drugs in Clinical Development 
In addition to the approved drugs described in the previous section, there are an increasing 
number of very hopeful new compounds in clinical development
37
. Agents targeting B-cell 
receptor signaling. B-cell receptor signaling seems to play an important role for the 
survival of CLL cells
38
. Different aspects of the B-cell-receptor have been recognized as a 
prognostic marker in chronic lymphocytic leukemia, such as immunoglobulin heavy chain 
variable gene (IGHV) or stereotypy. 
Continuous or repetitive BCR signaling supports CLL cell survival. This might explain 
why inhibition of BCR signaling is a new and potent strategy to treat CLL. The B-cell 
receptor signaling in CLL cells is supported by different tyrosine kinases, such as Bruton’s 
tyrosine kinase (BTK), Spleen tyrosine kinase (Syk), ZAP70, Src family kinases (in 
particular Lyn kinase) as well as PI3K
37
.  
Spleen tyrosine kinase, so called Syk, transfers and enhances the signal of the B-cell 
receptor. Activation of Syk results in cell survival through activation of 
phosphatidylinositol 3-kinases and AKT 
38
. The expression of Syk is upregulated in 
chronic lymphocytic leukemia cells turning it into a promising target
39
. 
Fostamatinib disodium, the first clinically available oral Syk inhibitor, induces apoptosis 
through disruption of B-cell receptor (BCL) signaling.  
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Class I phosphatidylinositol 3-kinases (PI3Ks) regulate cellular functions relevant to 
oncogenesis
40
. Expression of the PI3K p110 d isoform (PI3K- d) is restricted to cells of 
hematopoietic origin where it plays a key role in B cell proliferation and survival. In CLL 
the PI3K pathway is constitutively activated and dependent on PI3K d
41
. CAL-101 is an 
oral PI3Kd-isoformselective inhibitor, which promotes apoptosis in primary CLL cells in a 
time- and dose-dependent manner without inducing apoptosis in normal T cells or natural 
killer cells and without diminishing antibody-dependent cellular cytotoxicity. 
CAL-101 inhibits CLL cell chemotaxis toward CXCL12 and CXCL13 and migration 
beneath stromal cells (pseudoemperipolesis). CAL-101 also down-regulates secretion of 
chemokines in stromal cocultures and after BCR triggering
41
. CAL-101 reduces survival 
signals derived from the BCR or from nurse-like cells, and inhibits BCR- and chemokine-
receptor-induced AKT and MAP kinase (ERK) activation
41
. 
Bruton tyrosine kinase (Btk) leads to downstream activation of cell survival pathways such 
as NF-jB and MAP kinases via Src family kinases
42
. Ibrutinib (formerly called PCI-32765) 
is an orally active small molecule inhibiting Bruton’s tyrosine kinase (BTK) that plays a 
role in the signal transduction of the B-cell receptor (BCR). Inhibition of BTK might 
induce apoptosis in B-cell lymphomas and CLL-cells
42
.  
Dasatinib is a Src- and Abl- kinase inhibitor that induces apoptosis in primary CLL cells
43
. 
In addition Dasatinib seems to increase the apoptotic effects of various agents like 
fludarabine, chlorambucil, sorafenib, the HSP90 inhibitor 17-DMAG, dexamethasone, or 
the BH3- mimetic ABT-737
43
. In summary, dasatinib  seems effective in reduction of 
nodular tumor masses, but seems to lack efficacy on peripheral blood lymphocytes. 
Proteins in the B cell CLL/lymphoma 2 (Bcl-2) family are key regulators of the apoptotic 
process
44
. The Bcl-2 family comprises proapoptotic and prosurvival proteins. Shifting the 
balance toward the latter is an established mechanism whereby cancer cells evade 
apoptosis. Bcl-2, the founding member of this protein family, is encoded by the BCL2 
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gene which was initially described in follicular lymphoma as a protein in translocations 
involving chromosomes 14 and 18
45
. 
The Bcl-2 inhibitor ABT-263 (Navitoclax) and ABT-199. ABT-263 is a small molecule 
Bcl-2 family protein inhibitor that binds with high affinity (Ki_1 nM) to multiple anti-
apoptotic Bcl-2 family proteins including Bcl-XL, Bcl-2, Bcl-w, as well as Bcl-B and has a 
high oral bioavailability
46
. Initial studies showed very promising results for this drug as a 
single agent. However, its therapeutic use seemed somewhat limited by severe 
thrombocytopenias being a prominent side effect. Therefore, the compound was re-
engineered to create a highly potent, orally bioavailable and Bcl-2-selective inhibitor, 
ABT-199.  
AT101 is an orally active BH3-mimetic, which inhibits the anti-apoptotic activity of Bcl-2, 
Bcl-XL and Mcl-1 and might be an active agent for the treatment of CLL, as the resistance 
to apoptosis in CLL cells is associated with high levels of Bcl-2 protein expression. AT101 
was found to induce apoptosis in CLL cells in vitro and to overcome drug resistance 
mediated by the microenvironment
47
. It showed a good tolerability and satisfactory 
efficacy in combination with weekly infusions of rituximab in previously treated CLL 
patients
48
. 
1.1.3.5 Immunomodulatory drugs 
Lenalidomide is a second generation thalidomide analogue and an immunomodulatory 
agent with antiangiogenic properties that is used in treatment of myelodysplastic syndrome 
and multiple myeloma and is currently investigated in the treatment of CLL. It showed 
encouraging results in the treatment of high risk patients including carriers of a del(17p)
49
. 
In 58% of the patients lenalidomide causes a so called tumor flare reaction, which leads to 
a sensation of heat and burning in the lymph nodes and occurs only in CLL patients
50
.  
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The combination of lenalidomide and rituximab seems to increase the response rate 
without a higher risk of toxicity, even in patients with del(17p) and/or unmutated 
IGHVstatus. 
Everolimus has shown good efficacy in hematological malignancies
51
, in particular T-cell 
lymphoma, and was therefore tested in CLL as well. So far, the results in CLL have been 
disappointing with low response rates, and the enthusiasm for this drug has been further 
reduced by severe infectious complications. 
1.1.3.6 Combination chemotherapy 
A major advance in CLL treatment was achieved by the combined use of different 
treatment modalities, in particular for patients that had a good fitness. 
Since purine analogs and alkylating agents have different mechanisms of action and 
partially non-overlapping toxicity profiles, it seemed logical to combine the two modalities 
for achieving synergistic effects. Preclinical studies demonstrated that exposure of CLL 
cells to fludarabine and cyclophosphamide resulted in synergistic cytotoxicity
52
. 
Fludarabine has been evaluated in a variety of combination regimens. The combination of 
fludarabine with another purine analog, cytarabine, appeared to be less effective than 
fludarabine alone, while the combination of fludarabine with chlorambucil or prednisone 
increased hematological toxicity without improving the response rate compared with 
fludarabine alone
53
.  
1.1.3.7 Chemoimmunotherapy 
Since preclinical studies showed evidence for a synergy between rituximab and 
fludarabine
54
, rituximab combinations with fludarabine or fludarabine-based regimens 
were investigated in Phase II trials. The synergistic activity of fludarabine and 
alemtuzumab was initially suggested by the induction of responses, including one CR, in 5 
of 6 patients who were refractory to each agent alone
55
.  
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The combination of alemtuzumab with rituximab has also been studied in patients with 
lymphoid malignancies, including those with refractory/relapsed CLL, producing an ORR 
of 52% (8% CR; 4% nodular PR, nPR; 40% PR)
56
. These results need to be confirmed by 
larger trials. 
1.1.3.8 Selecting of the Right Treatment: 
Parameters to be considered 
Given the impressive choice of options, the right choice of treatment of a given CLL a 
patient becomes a task that requires experience, a good clinical judgment and an 
appropriate use of diagnostic tools. The following parameters should be considered before 
recommending a treatment for CLL
26
: 
1. The clinical stage of disease. 
2. The fitness of the patient. 
3. The genetic risk of the leukemia. 
4. The treatment situation (first versus second line, response versus non-response of the 
last treatment). 
 
1.1.4Immunophenotyping 
CLL cells co-express the T-cell antigen CD5 and B-cell surface antigens CD19, CD20, and 
CD23
57
. The levels of surface immunoglobulin (Ig), CD20, and CD79b are 
characteristically low compared to those found on normal B cells
170
. Each clone of 
leukemia cells is restricted to expression of either kappa or lambda immunoglobulin light 
chains. In contrast, B-cell PLL cells do not express CD5 in half of the cases, and typically 
express high levels of CD20 and surface Ig . Also, the leukemia cells of mantle cell 
lymphoma, despite also expressing B cell surface antigens and CD5, generally do not 
express CD23. The chronic lymphoid leukemias comprise a number of biologically distinct 
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neoplasms of mature lymphocytes
57
. The availability of specific therapies for  certain of 
these tumors makes accurate diagnosis imperative. In most cases, detailed 
immunophenotypic analysis of the chronic lymphoid leukemias permits specific 
classification and initiation of the most appropriate therapy. For example, the characteristic 
immunophenotype of B-cell chronic lymphocytic leukemia (CLL): CD5+, CD23+, FMC7-
, CD20 dim+, clonal surface immunoglobulin (sIg) dim+, distinguishes it from another 
CD5+ B-cell lymphoproliferative disorder, mantle cell lymphoma, which typically displays 
the composite phenotype: CD5+, CD23-, FMC7+, CD20 bright+, clonal sIg bright+. 
Likewise, hairy cell leukemia has a characteristic immunophenotype: CD5-, CD11c 
bright+, CD25+, CD103+, which distinguishes it from other CD5- B-cell 
lymphoproliferative disorders, including the morphologically similar splenic lymphoma 
with circulating villous lymphocytes. Immunophenotypic analysis by flow cytometry may 
also identify clinically relevant subsets of patients within a diagnostic category of 
leukemia. Thus, in patients with CLL, deviation from the typical immunophenotype is 
associated with trisomy 12 and mixed-cell morphology. In summary, careful 
immunophenotyping by flow cytometry facilitates accurate diagnosis in the chronic 
lymphoid leukemias, and in some settings, may also offer additional therapeutically 
relevant information. Several studies have shown that immunophenotypic analysis of 
neoplastic cells is of great help for the investigation of minimal residual disease (MRD). 
This is mainly due to the fact that flow cytometry immunophenotyping is more sensitive 
than morphology in detecting residual leukemic cells. Additionally, immunophenotyping 
has proved to be of utility for evaluating the effectiveness of high-dose chemotherapy and 
for predicting relapses. 
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1.2 ZAP-70 
 
Chronic lymphocytic leukemia (CLL) is a small mature B-cell neoplasm that usually 
expresses CD5 along with CD23 and displays a variable clinical course. A well-established 
prognostic marker identified over 10 years ago that can help distinguish patients with CLL 
with aggressive disease from those that have more indolent clinical courses is the mutational 
status of the expressed immunoglobulin heavy chain variable (VH) gene
58
. Patients with CLL 
that use mutated VH gene (less than 98% homology to the germline counterparts) may not 
require treatment for 20 years or more following diagnosis. In contrast, patients with CLL that 
express unmutated VH genes (98% or more homology to the germline counterparts) often 
require treatment after a few years following diagnosis and have shorter survival. Since these 
findings, information regarding the mutational status of IgVH has become of considerable 
value in the prognostic assessment of B-CLL patients. However, IgVH mutational analysis is 
still a complex and time-consuming procedure, not yet routinely performed in most 
laboratories.
60
 Therefore, many subsequent studies focused on the identification of alternative 
markers with similar prognosticvalue to that of IgVh mutations, and whose expression could 
be investigated by flow cytometry. The recently introduced techniques of gene expression 
profiling(GEP) have been also used for the identification of additional molecules to be 
employed as potential prognosticators in B-CLL. Amog them, the gene encoding for the T 
cell specific zeta-associated protein 70 (ZAP-70), firstly identified by GEP, has been 
demonstrated to have both prognostic relevance and predictive power as surrogate for IgVH 
gene mutations, when its expression is investigated by flow cytometry. Subsequent gene 
expression profiling studies indicated that expression of ZAP-70 was very good at 
differentiating CLL with mutated VH genes from CLL cases expressing unmutated VH genes. 
These findings opened up the possibility that ZAP-70 expression analysis of CLL could be 
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used as a surrogate marker of VH mutational status and be developed as a relatively simple 
clinical test. 
59
 
 There are two different approaches to define if a given B-CLL population has to be 
considered positive for ZAP-70 expression. The first one , in analogy to standard procedures 
of flow cytometry staining, is based on the signal obtained by using a irrelevant isotype-
matched control Mab; according to this method, B-CLL cells are defined as ZAP-70 positive 
when the expression levels of the protein exceed those of its corresponding isotypic control. 
The other method is based on the expression level of ZAP-70 in normal T and NK cells of the 
same sample, which are known to constitutively express the protein, as a sort of internal 
positive control; according to this latter strategy, B-CLL cells are defined as ZAP-70 positive 
when they express ZAP-70 protein at levels comparable to those found in ZAP-70 expressing 
T and NK cells. The cut-off level used to define the ZAP-70 category (positive or negative) of 
a given B-CLL sample differs in the various studies, usually ranges fron 10% to 20% of 
positive cells.
61
 
In theory, flow cytometry is particularly well suited for clinical evaluation of ZAP-70 in part 
because CLL cells and normal T-cells, which are often present in peripheral blood specimens 
and express high levels of ZAP-70, can be separately analyzed. However, flow cytometric 
analysis of ZAP-70 has proven to be problematic as differences in antibodies, 
permeabilization techniques, negative controls, and/or other procedures can lead to discordant 
results between different laboratories and variable degrees of correlation with VH mutational 
status or clinical data . Many of these problems are likely related to suboptimized detection of 
ZAP-70 and only weak positive ZAP-70 staining has been achievable using currently 
available antibodies. Moreover, because of weak ZAP-70 related staining, the method used to 
set a threshold to remove background staining is critical and can have a major impact on the 
reported ZAP-70 value. In addition, because well-established methods generate a continuum 
of ZAP-70 levels among CLL cases, the significance intermediate ZAP-70 values may have 
19 
 
to prognosis is difficult to interpret without individual laboratories also performing clinical 
correlation and/or VH mutation studies. A key feature is the use of isotypic controls at 
concentrations that differ from those recommended by the suppliers but selected to insure 
normal peripheral blood B-cells are ZAP-70 negative. Although ZAP-70 appears to be 
expressed in early normal B-cell development, and in activated B-cells by Western blot 
analysis of sorted cells, mature peripheral blood B-cells are ZAP-70 negative using this 
sensitive method.
62 
Among the available prognostic immunophenotypic markers in CLL, zeta-chain-associated 
protein kinase 70 (ZAP-70) is one of the most promising markers because of its strong 
correlation with IGHV mutational status. Flow cytometric analysis of ZAP-70 gives an 
advantage of the simultaneous assessment of its levels in the clonal B-cell as well as the 
residual T- and NK-cells (internal positive control), and normal remaining (NR) B-cell 
(internal negative control). However, the detection of this intracellular protein needs to be 
robust and reproducible in order to reduce intra-laboratory variations. This means that the 
intrinsic variability of blind replicate must be strictly controlled. An early step in this 
direction was the introduction of the use of a normal donor sample as an external control for 
ZAP-70 assessment. This was previously described by Rassenti et al. using normal donor T-
cells as a reference for ‘‘percent of positive cells’’. More recently, a normalization step of 
adding B-cells from a pool of normal donor peripheral blood mononuclear cells constitutes a 
second step toward standardization. A study previously reported the advantage of using two 
clones for ZAP-70 expression analysis and utilizing normal donor blood as a reference 
control. Flow cytometric detection of ZAP-70 in CLL has proven to be technically 
challenging and generates variable results depending on the particular methods used for 
staining and analysis.
63
 As the intensity of ZAP-70 staining in positive CLL cases is typically 
low, the choice of controls and/or method to set a threshold to distinguish positive staining 
from nonspecific background staining is critically important. Controls used for ZAP-70 
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analysis include internal CLL specimen T-cell positive controls, internal CLL specimen 
normal B-cells negative controls, and external B-cells from a normal donor negative controls. 
However, all of these have potential problems in that T-cells in patients with CLL may not be 
normal and can show variable ZAP-70 expression levels. Similarly, CD5 negative B-cells in 
patients with CLL may also be abnormal and possibly activated due to interactions with the 
CLL or T-cell populations, which could affect ZAP-70 levels, and are often not present in 
sufficient numbers to adequately characterize in many specimens. Setting a negative threshold 
based on ZAP-70 staining of external B-cells from a normal donor peripheral blood specimen, 
although attractive, does not take into account possible differences in nonspecific staining 
properties of CLL cells relative to B-cells due to CLL cell size or other membrane/cytologic 
properties that could be present in many cases. The use of isotypic control antibodies to set a 
negative threshold differs from prior flow cytometry studies of ZAP-70 expression in CLL 
that also used isotypic controls and also eliminates problems that can be associated the use of 
isotypic controls. It is well known that monoclonal isotype controls are often selected for low 
binding activity and have different nonspecific binding properties relative to the monoclonal 
antibodies they are parried with so are not necessarily good negative controls, even when used 
at the same concentrations. In addition, differences between isotypic controls and test 
antibodies with respect to fluorochrome to protein labeling or manufacturing can also 
contribute to the unreliability of isotypic controls. Moreover, all of these issues are potentially 
more problematic when staining cytoplasmic antigens such as ZAP-70 where the effects of 
fixation, permeabilization, and antibody trapping can come into play and further affect 
nonspecific antibody binding. Insuring normal B-cells appear ZAP-70 negative relative to an 
isotypic control effectively compensates for any differences in nonspecific binding properties 
and/or F:P ratios between isotype and the ZAP-70 antibody. The only assumption using our 
‘‘experimentally matched’’ isotypic control method is that the physical or cellular properties 
affecting nonspecific binding of antibody to CLL cells are the same as those affecting 
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nonspecific binding to normal B-cells. Interestingly, Hassanein et al. also recently reported 
finding a bimodal distribution of ZAP-70 expression among 125 CLL cases analyzed using 
the same antibody we employ with a trough around 40% which is similar to the gap in our 
distribution that occurred between values of 30–60%.64 A bimodal as opposed to continuous 
distribution of ZAP-70 values may be related to greater precision and/or sensitivity of our 
assay due in part to previous optimization of the staining procedure by use of a 
noncommercial saponin fixation step and performing Scatchard analysis of binding curves to 
select antibody concentrations that give the highest signals relative to background staining. 
Moreover, many laboratories run a single external B-cell control, which could also diminish 
the precision of the resultant ZAP-70 values because of variable B-cell staining among 
different individuals. Using an optimized isotypic control threshold appears to be necessary to 
obtain a bimodal distribution, because use of a ZAP-70 stained external B-cell threshold 
generated a continuous distribution of ZAP-70 values similar to that reported by Rassenti et 
al.  with the same staining procedure. In summary, use of our experimentally optimized 
isotypic control method for assessing ZAP-70 expression in CLL cases has the potential to 
improve interpretation by placing the resultant ZAP-70 values in one of two groups, and 
generating better correlation with VH mutational status compared with other methods 
65
.  
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1.3 CLLU-1 
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a highly variable 
outcome depending on clinical and biological characteristics. Clinical staging is a relatively 
simple method of assessing the outcome of CLL patients based on clinical parameters. In the 
last two decades, multiple biological markers have been shown to have prognostic relevance 
in CLL, most notably chromosomal aberrations, IGHV mutations and expression of surface 
markers such as ZAP-70 and CD38. 
Gene expression analyses have also revealed the heterogeneity of CLL, with distinct gene 
expression signatures being associated with particular genetic subgroups of CLL In particular, 
the expression of genes such as CLLU1, and LPL have recently been associated with different 
outcomes in CLL.
67 
CLLU1 located at chromosome 12q22, encodes a novel transcript, which has been identified 
as a marker specific to CLL.In particular, high CLLU1 expression (CLLU1-H) is significantly 
more frequent in unmutated IGHV and CD38+ CLL. CLLU1-Hh as been shown to be 
associated with shorter overall survival and shorter time to first treatment in patients with 
early stage CLL, especially those younger than 70 years. In addition, CLLU1 expression has 
been shown to be a specific and stable marker in CLL cells, making it a promising marker not 
only for prognosis but also for minimal residual disease analysis. However, the effect of 
CLLU1 expression on response to therapy is currently unknown and, to date, there are no data 
on the significance of CLLU1 expression with regards to progression-free survival and overall 
survival in patients receiving first-line therapy. We assessed the value of CLLU1 expression 
as a prognostic marker in the LRF CLL4 randomized controlled trial. CLLU1, located at 
chromosome 12q22, encodes a transcript specific to chronic lymphocytic leukemia and has 
potential prognostic value.
68
 However, CLLU1 expression was not an independent predictor 
of overall survival in a multivariate model including TP53 aberrations, beta-2 microglobulin 
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level, age and IGHV mutation status. Nor did it predict response to treatment. CLLU1 
expression analysis helps to refine the prognosis of patients with chronic lymphocytic 
leukemia who have mutated IGHV genes. The accurate diagnosis of B-cell lymphocytosis has 
important prognostic and therapeutic implications. The distinction of chronic lymphocytic 
leukemia (CLL) from other B-cell neoplasms, however, can be difficult since leukemic 
manifestations of mantle cell lymphoma (MCL) and splenic marginal zone lymphoma 
(SMZL) can be morphologically indistinguishable and can immunophenotypically overlap 
with CLL. The diagnostic scoring system for the specific immunophenotype of CLL proposed 
by Matutes et al. comprises a set of five markers which have proven to be useful in many 
cases . In cases with 2 or 3 of five markers, additional parameters are needed to establish the 
correct diagnosis. A number of surface and molecular markers have been investigated and 
proposed to be diagnostically useful and/or to have prognostic significance in B-cell 
lymphocytosis, five of which have recently been combined into a new molecular scoring 
system for risk stratification for CLL, including ZAP70, LPL (lipoprotein lipase), CLLU1, 
microRNA-29c and microRNA-223. The chronic lymphocytic leukemia upregulated gene-1 
(CLLU1) has been shown to be the first highly specific CLL gene . Six tran-scripts have been 
identified, two of which contain a putative coding sequence with low similarity to human 
interleukin-4. Overexpres-sion of the transcript cDNA1 appears to be specific for CLL, is of 
prognostic significance and can be used for MRD detection. High levels of CLLU1 
expression in patients with CLL have been correlated with unfavorable prognostic markers, 
i.e. unmutated IgVH, high CD38 expression, high ZAP70 expression and unfavorable 
cytogenetics (17p, 11q).
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2 THE AIM OF WORK 
The aim of work it was to apply a single tube to analyze expression of ZAP-70  by 
multiparametric flow cytometry assay in healthy donors and in B-CLL patients and to 
analyze expression of CLLU-1 in the same samples  
Our goal is to show that a poor clinical outcome and a bad response to therapy is 
observed in patients with ZAP-70+, and high CLLU1 expression levels and to show a 
possible correlation of the above topics with other aberrations (atypical morphology, 
atypical immunophenotype). 
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3MATERIALS AND METHODS  
3.1 B-CLL Patients and controls 
The study includes peripheral blood samples, collected after informed consent for 
diagnostic purposes, from healthy donors and 20 patients affected by B-CLL. PB 
mononuclear cells were isolated by centrifugation on Ficoll-hypaque gradient, suspended 
in PBS 10% dimethylsulphoxide, and stored in liquid nitrogen until use. 
 
3.2Analysis for ZAP-70 
We have performed a simple flow cytometry assay for ZAP-70. Peripheral blood (PB) 
samples from 5 healthy donor and 20 B-CLL patients was processed and analyzed by 
flow cytometry within 24 hours. 50 µl or approximately 10 x 10
6
 cells of each samples 
were incubated for 15 minutes in the dark at room temperature with the following 
monoclonal antibodies: anti CD3-PerCP, anti CD5 Fitc, anti CD45 APC Cy-7, anti CD19 
PE Cy-7, anti-CD38-APC. Then they were treated with 100 µl of reagent A from BD 
Intrasure Kit for 5 minutes, then treated with lysing solution for 10 minutes and finally 
stained with the anti-human/mouse ZAP-70 R-PE conjugated. All samples were analyzed 
on a BD FACSCANTO II using FACS-DIVA software. Up to 100000 events were 
acquired per tube.  
3.3 Samples preparation  
CD19+ cells of donors was magnetically labelled with Whole Blood CD19 MicroBeads. 
Then, the cell suspension was applied onto a MACS Column, which was placed in the 
magnetic field of MACS separator. The magnetically labelled CD19+ cells were retained 
within the column. After removing of the column from the magnetic field, the 
magnetically retained CD19+ cells were eluted as positively selected cell fraction. 
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3.4 Quantitative reverse transcriptase-polymerase chain reaction (QRT-
PCRs) 
Quantification of CLLU1 expression in CD19+ cells of donors and buffy coat of patients 
was performed with the use of CLLU-1 ProfileQuant Kit (Ipsogen) by RQ-PCR. An 
endogenous control (beta2-microglobulin transcript) is amplified from the sample as well 
as CLLU-1 transcript. Standard curve of known amounts of both the endogenous B2 M 
control and the CLLU-1 cDNA allow the calculation of the ratio of CLLU1 signal to 
endogenous B2M signal in each sample. Normalised copy number is given of the ratio of 
CLLU1 CN/ B2M CN.  
3.5Statistical analysis 
Relation between B MFI/T MFI of ZAP-70 positive patients versus healthy donors, ZAP-
70 negative patients versus healthy donors and expression of CLLU-1 between B-CLL 
patients and healthy donors was assessed using t-test. 
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4 RESULTS AND DISCUSSION 
 Among immunophenotypic markers also associated with prognosis of B-CLL , ZAP-70 
expression is one of the most promising because of its strong correlation with IgH 
mutational status. ZAP-70, a member of the Syk–ZAP-70 protein tyrosine kinase family, is 
normally expressed in T and natural killer cells and has a critical role in initiation of T-cell 
signaling. Recent studies have found that ZAP-70 is associated with enhanced signaling by 
the cell surface immunoglobulin receptor in CLL B cells and that measurement of ZAP-70 
can serve as a surrogate for mutational status of IgVH. ZAP-70 is an independent negative 
prognostic marker in chronic lymphocytic leukemia (CLL). Usually, its expression is 
investigated by flow cytometric protocols in which the percentage of ZAP-70 positive CLL 
cells is determined in respect to isotypic control (ISO-method) or residual ZAP-70 positive 
T cells (T-method). The first approach is based on the signal obtained using an isotype-
matched antibody as negative control. Accordingly, a CLL sample is defined as ZAP-70 
positive when at least 20% of CLL cells have a signal exceeding that of isotypic control. 
The second approach is based on the expression of ZAP-70 on normal T cells, which 
constitutively express the protein and hence are utilized as an internal positive control. 
Following this strategy, a CLL sample is defined as ZAP-70 positive when at least 20% of 
CLL cells express ZAP-70 at levels comparable to those found in the residual T cell 
component. 
Also CD38 positivity as well as the other biological variables were able to segregate 
intermediate risk patients who experienced a shorter survival. The prognostic significance 
of CD38 expression on clinical outcome of B-CLL patients was also corroborated by the 
results of the multivariate analysis. Therefore, some studies proposes CD38 expression as 
a novel and significant prognostic indicator that delineates similar overlapping groups of 
B-CLL patients. In addition, this parameter can be determined easily and rapidly by flow 
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cytometry in most hematologic laboratories, and, consequently, it may be a very useful 
addition to the current staging systems. Actually, this simple test may enable physicians to 
accurately predict a favourable or an unfavourable clinical course. Experience suggests 
that CD38 positive  B-CLL patients have a progressive and an unfavourable disease. 
Despite these important clinical observations, the reason why Ig VH gene mutation status 
and expression of ZAP-70 and CD38 influence or correlate with disease progression are 
still undefinited. Cells of patients with CLL may express surface IgM with polispecific 
(natural) antibody activity and bind to a variety of different antigens, including self-
antigens. This specificity, however, is detected rarely for surface IgM from unmutated 
CLL cases. This findings led to hypothesis that the reaction between surface IgM of 
unmutated CLL cases and self antigens induces cell activation and that continuous 
stimulation would favour expansion of unmutated CLL clones in vivo. In contrast, cells 
from mutated cases would not be stimulated via their surface IgM , and their expansion 
would be more indolent. Tentatively, it could also be proposed that activation through 
surface IgM induces the expression of both ZAP-70 and CD-38, inasmuch as both these 
structures are activation markers for normal B cells. Moreover, they could be involved in 
the IgM-dependent signal trasduction pathway, although this issue is still controversial. 
CLLU1 is a novel gene, located at chromosome 12q22, up regulated selectively in chronic 
lymphocytic leukaemia (CLL) cells and highly expressed in patients with adverse 
prognostic factors such as high ZAP-70 and CD38 expression or unmutated genes 
encoding variable regions of the immunoglobulin gene (IgVH). High levels of CLLU1 
expression were associated with shorter overall survival (P < .001), with a 7% increase in 
risk of early death by each doubling of the CLLU1 expression level. Stratification for age 
at diagnosis demonstrated a strong prognostic significance of CLLU1 expression in 
patients younger than 70 years (P < .001). Quantification of CLLU1 expression was 
performed with the use of TaqMan One-Step RT-PCR  
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The lymphocyte population was gated on side-scatter versus CD45 plot. ZAP-70 
expression was determinated on B and T. CD3 cells were displayed in a side scatter 
versus fluorescence (CD3 Per-CP) gated on lymphocyte population. CD19 cells were 
displayed in a fluorescence (CD19 PE-Cy7) versus fluorescence (CD5 APC) dot-plot 
gated on lymphocyte population. To quantify ZAP-70 expression , we used a method in 
which the identification of ZAP-70+ population was driven by an internal positive 
control represented by the population of normal T cells (Fig.1). Following this method, a 
CLL sample was defined as ZAP-70 positive when at least 30% of CLL cells express 
ZAP-70 at levels comparable to those found in the residual T cell. 
Analysis of ZAP-70 expression in B and T cells was performed by calculating the mean 
fluorescence intensity (MFI) of each populations and the ratio (MFIR) between the MFI 
of B-cells and MFI of T cells. (Tab. 1).  
About ZAP-70 expression we have analyzed 5 healthy donors and 20 B-CLL patients and 
we measured the same parameters and determinate the same statistic indexes (means and 
standard deviation for each parameters). All healthy donors showed negative values about 
ZAP-70 expression, while seven patients showed positive values about the same 
parameter. 
Comparing values of the ratio of B MFI and T MFI between ZAP-70 positive patients and 
ZAP-70 negative patients we have found these populations were significantly different 
with a p-value = 0,0034 (Fig.3), instead the difference B MFI/ TMF T between negative 
patients and controls was non-significant with p-value = 0,2134 (Fig.4). 
About CLLU-1 the difference between CLLU-1 expression levels of donors versus B-
CLL patients was significant with p value = 0,0366. (Fig.5) 
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5 FIGURES: 
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Fig1: Evaluation of ZAP-70 expression in a healthy donor. Dot plots A, B, C show the 
gating regions to select lymphocytes, B-cells and T-cells. D shows the method of analysis 
used to quantify expression of ZAP-70 by B-cells. 
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Fig2: Evaluation of ZAP-70 expression in a B-CLL patient Dot plots A, B, C show the 
gating regions to select lymphocytes, B-cells and T-cells. D shows the method of analysis 
used to quantify expression of ZAP-70 by B-cells. 
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6 TABLES:  
donors Ly % T% B % %ZAP 70 positive cells MFI-T MFI-B B/T 
CLLU-
1/B2M*100 
C1 29,4 63,2 13,9 2,3 1304 149 0,114264 0,002 
C2 39,3 76,7 12,6 28,1 1089 189 0,173554 0,005 
C3 29,2 84 2 17,6 1249 296 0,23699   
C4 40,3 71,2 8,5 6,3 949 336 0,354057 0,007 
C5 32,1 69,4 5,7 2 1011 123 0,121662 0,004 
mean 34,06 72,9 8,54 11,26 1120,4 218,6 0,200105 0,0045 
ds 5,375221 7,856208 4,900306 11,34032627 152,1342 93,04999 0,088644 0,00212132 
Tab 1: Percentage of total, B and T lymphocytes, ZAP-70 positive cells, T-MFI, B-MFI, B-
MFI/TMFI and CLLU-1 expression in donors. 
 
Patients Ly % T% B % %ZAP 70 positive cells MFI-T MFI-B B/T 
CLLU-1/B2 
M*100 
P1 96,9 2,5 95,3 0,1 1367 283 0,207023 0,495 
P2 91,6 36,2 63,3 60 1341 881 0,656972   
P3 94 2,1 95,8 53,7 2310 871 0,377056   
P4 90,3 3,9 94,5 28 2517 702 0,278903   
P5 88,5 4,2 92,8 21,9 1148 322 0,280488 0,253 
P6 95 19,3 67,9 46,2 998 363 0,363727 0,345 
P7 84,3 94,7 2,9 0,6 1795 178 0,099164   
P8 75,5 13,6 76,4 11,8 1390 765 0,55036 0,08 
P9 86,6 5 85,5 4,9 2249 322 0,143175   
P10 62,1 21,7 65,9 6,8 542 117 0,215867 0,031 
P11 82,6 10,9 81,5 11,4 2007 619 0,308421   
P12 88,6 10,5 85,7 30,6 1078 471 0,43692 0,24 
P13 69,5 30,1 58,5 70,7 1587 635 0,400126 0,03 
P14 85,4 30,1 64,4 25,3 2266 521 0,229921 0,01 
P15 93,9 2,3 92,8 18,1 2473 982 0,397089 0,462 
P16 67,1 13,7 75,7 1,6 1069 219 0,204864   
P17 79,5 6,4 87,5 24,4 1659 490 0,295359 0,025 
P18 88 3,5 92,9 34,1 1824 693 0,379934 0,253 
P19 94,6 3,1 95,2 13,6 1617 559 0,345702 0,275 
P20 53,9 31,9 48,2 95,3 2720 1977 0,726838   
mean 83,395 17,285 76,135 27,955 1697,85 598,5 0,344895 0,212785714 
SD 11,98699 21,41623 22,42931 25,67227616 593,764 406,959 0,159637 0,172496706 
 
Tab 2: Percentage of total, B and T lymphocytes, ZAP-70 positive cells, T-MFI, B-MFI, B-
MFI/TMFI and CLLU-1 expression in B-CLL patients. 
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Fig 3: B MFI/ T MFI in ZAP-70 positive patients and in ZAP-70 negative patients 
 
 
 
 
 
Fig 4: B MFI/ T MFI in healthy donors and in ZAP-70 negative patients 
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Fig. 5: Normalised copy number of CLLU-1 gene in healthy donors and in B-CLL patients. 
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Patients Time diagnosis Stage Disease at diagnosis Therapy Genetic delections disease course CLLU-1/B2*100 B/T
P1 2003 II di Binet yes 11q22.3 progress 0,495 0,21
P5 2006 II Binet yes normal  progress 0,253 0,28
P6 2011 I di Rai no normal no progress 0,345 0,36
P8 2010 0 di Rai no 13q 14.3 no progress 0,08 0,55
P10 2010 II di Rai no normal no progress 0,031 0,22
P12 2008 0 di Rai yes normal progress 0,24 0,44
P13 2010 0 di Rai no normal no progress 0,03 0,40
P14 2012 I di Rai no normal no progress 0,01 0,23
P15 2009 0 di Rai no 13 q 14.3 NA 0,462 0,40
P17 2007 I di Rai NA NA NA 0,025 0,30
P18 2008 I di Rai no normal progress 0,253 0,38
P19 2010 I di Rai no 13q 14.3 no progress 0,275 0,35  
 
Fig 6: Patient characteristics 
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Fig 7: B MFI/ T MFI and normalised copy number of CLLU-1 gene 
 
r = -0,019 
t = -0,059 
p = 0,954  NS 
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